NRL-1049(BA 1049) is a small molecule selective inhibitor of ROCK2 with an IC50 of 0.59 µM. It exhibits potent efficacy in preserving the blood-brain barrier (BBB) and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.

NRL-1049(BA 1049) is a small molecule selective inhibitor of ROCK2 with an IC50 of 0.59 µM. It exhibits potent efficacy in preserving the blood-brain barrier (BBB) and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.

NRL-1049(BA 1049) is a small molecule selective inhibitor of ROCK2 with an IC50 of 0.59 µM. It exhibits potent efficacy in preserving the blood-brain barrier (BBB) and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.

NRL-1049(BA 1049) is a small molecule selective inhibitor of ROCK2 with an IC50 of 0.59 µM. It exhibits potent efficacy in preserving the blood-brain barrier (BBB) and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.

JNT-517 is a selective and orally bioavailable inhibitor of SLC6A19, with an IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay. JNT-517 treatment increases urinary excretion of phenylalanine (Phe) in a mouse model of phenylketonuria (PKU), thereby reducing plasma Phe levels.

JNT-517 is a selective and orally bioavailable inhibitor of SLC6A19, with an IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay. JNT-517 treatment increases urinary excretion of phenylalanine (Phe) in a mouse model of phenylketonuria (PKU), thereby reducing plasma Phe levels.

JNT-517 is a selective and orally bioavailable inhibitor of SLC6A19, with an IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay. JNT-517 treatment increases urinary excretion of phenylalanine (Phe) in a mouse model of phenylketonuria (PKU), thereby reducing plasma Phe levels.

JNT-517 is a selective and orally bioavailable inhibitor of SLC6A19, with an IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay. JNT-517 treatment increases urinary excretion of phenylalanine (Phe) in a mouse model of phenylketonuria (PKU), thereby reducing plasma Phe levels.

Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).

Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).